Acta Haematol

1. NASNAS PE, Jabbour EJ, Sasaki K, Issa GC, et al
   Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia.
   Acta Haematol. 2024 Apr 4. doi: 10.1159/000538651.
   

   >> Share

   
   

   
   Am J Hematol

2. CRAMER P, von Tresckow J, Fink AM, Robrecht S, et al
   Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
   Am J Hematol. 2024 Apr 5. doi: 10.1002/ajh.27304.
   

   >> Share

   
   
3. MUSICK JO, Williams EK, Fibben KS, Zhang DY, et al
   Redefining hyperviscosity in acute leukemia: Potential implications for red cell transfusions in the microvasculature.
   Am J Hematol. 2024 Apr 4. doi: 10.1002/ajh.27308.
   

   >> Share

   
   
4. KHAN AA, James D, Andresen V, Atkey J, et al
   Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations.
   Am J Hematol. 2024 Apr 3. doi: 10.1002/ajh.27301.
   

   >> Share

   
   

   
   Ann Hematol

5. PEREZ-LAMAS L, de Paz Arias R, Diaz RMA, Montero LFC, et al
   Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.
   Ann Hematol. 2024 Apr 3. doi: 10.1007/s00277-024-05662.
   

   >> Share

   
   
6. WANG J, Zhu H, Miao K
   Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report.
   Ann Hematol. 2024 Apr 1. doi: 10.1007/s00277-024-05714.
   

   >> Share

   
   

   
   Blood

7. MARCAIS A
   Targeting PD-L1 to treat ATLL?
   Blood. 2024;143:1320-1322.
   

   >> Share

   
   
8. MINA A, Greenberg PL, Deeg HJ
   How I reduce and treat posttransplant relapse of MDS.
   Blood. 2024;143:1344-1354.
   

   >> Share

   
   
9. BASTIAN L, Beder T, Barz MJ, Bendig S, et al
   Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
   Blood. 2024;143:1391-1398.
   

   >> Share

   
   

   
   BMC Cancer

10. ROULEAU M, Villeneuve L, Allain EP, McCabe-Leroux J, et al
    Non-canonical transcriptional regulation of the poor prognostic factor UGT2B17 in chronic lymphocytic leukemic and normal B cells.
    BMC Cancer. 2024;24:410.
    

    >> Share

    
    

    
    Bone Marrow Transplant

11. MAFFINI E, Labopin M, Kroger N, Finke J, et al
    Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Bone Marrow Transplant. 2024 Mar 30. doi: 10.1038/s41409-024-02275.
    

    >> Share

    
    

    
    Cancer

12. DUFFY C, Hunger SP, Bhakta N, Denburg AE, et al
    Curing pediatric cancer: A global view. Examples from acute lymphoblastic leukemia.
    Cancer. 2024 Mar 29. doi: 10.1002/cncr.35290.
    

    >> Share

    
    
13. WANG X, Zhang B, Zhang Q, Zhou H, et al
    Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia.
    Cancer. 2024 Apr 5. doi: 10.1002/cncr.35316.
    

    >> Share

    
    

    
    Cancer Res

14. BOET E, Sarry JE
    Targeting Metabolic Dependencies Fueling the TCA Cycle to Circumvent Therapy Resistance in Acute Myeloid Leukemia.
    Cancer Res. 2024;84:950-952.
    

    >> Share

    
    

    
    Eur J Haematol

15. ISHIKAWA C, Mori N
    Pivotal role of dihydroorotate dehydrogenase as a therapeutic target in adult T-cell leukemia.
    Eur J Haematol. 2024 Apr 1. doi: 10.1111/ejh.14209.
    

    >> Share

    
    

    
    Exp Cell Res

16. ENLUND S, Sinha I, Neofytou C, Amor AR, et al
    The CNS microenvironment promotes leukemia cell survival by disrupting tumor suppression and cell cycle regulation in pediatric T-cell acute lymphoblastic leukemia.
    Exp Cell Res. 2024 Mar 30:114015. doi: 10.1016/j.yexcr.2024.114015.
    

    >> Share

    
    

    
    Exp Hematol

17. PANTING RG, Kotecha RS, Cheung LC
    The critical role of the bone marrow stromal microenvironment for development of drug screening platforms in leukemia.
    Exp Hematol. 2024 Mar 27:104212. doi: 10.1016/j.exphem.2024.104212.
    

    >> Share

    
    

    
    Int J Hematol

18. TODA Y, Ashizawa M, Murahashi R, Nakashima H, et al
    Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era.
    Int J Hematol. 2024 Apr 5. doi: 10.1007/s12185-024-03752.
    

    >> Share

    
    

    
    J Immunol

19. HAY ZLZ, Kim DD, Cimons JM, Knapp JR, et al
    Granzyme F: Exhaustion Marker and Modulator of Chimeric Antigen Receptor T Cell-Mediated Cytotoxicity.
    J Immunol. 2024;212:1381-1391.
    

    >> Share

    
    

    
    Leuk Res

20. BRUNETTI M, Iasenza IA, Jenner AL, Raynal NJ, et al
    Mathematical modelling of clonal reduction therapeutic strategies in acute myeloid leukemia.
    Leuk Res. 2024;140:107485.
    

    >> Share

    
    
21. IKOMA-COLTURATO MRV, Severino AR, Dos Santos Tosi JF, Bertolucci CM, et al
    Clinical validation of a 10-color flow cytometry panel to detect measurable residual disease in acute myeloid leukemia.
    Leuk Res. 2024;140:107482.
    

    >> Share

    
    

    
    Leukemia

22. BORDINI J, Lenzi C, Frenquelli M, Morabito A, et al
    IkappaBepsilon deficiency accelerates disease development in chronic lymphocytic leukemia.
    Leukemia. 2024 Apr 4. doi: 10.1038/s41375-024-02236.
    

    >> Share

    
    
23. JASSINSKAJA M, Ghosh S, Watral J, Davoudi M, et al
    A complex interplay of intra- and extracellular factors regulates the outcome of fetal- and adult-derived MLL-rearranged leukemia.
    Leukemia. 2024 Mar 30. doi: 10.1038/s41375-024-02235.
    

    >> Share

    
    

    
    PLoS One

24. 
    Retraction: Sensitive Detection of Pre-Existing BCR-ABL Kinase Domain Mutations in CD34+ Cells of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients Is Associated with Imatinib Resistance: Implications in the Post-Imatinib Era.
    PLoS One. 2024;19:e0301946.
    

    >> Share

    
    
25. MESSLING JE, Pena-Romer I, Moroni AS, Bruestl S, et al
    RIO-kinase 2 is essential for hematopoiesis.
    PLoS One. 2024;19:e0300623.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share